Last reviewed · How we verify
CK-3773274 - Tablets
At a glance
| Generic name | CK-3773274 - Tablets |
|---|---|
| Sponsor | Cytokinetics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). (PHASE2, PHASE3)
- A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy (PHASE3)
- Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM (PHASE3)
- Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy (PHASE2)
- Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM (PHASE3)
- Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM (PHASE2, PHASE3)
- Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM (PHASE3)
- A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CK-3773274 - Tablets CI brief — competitive landscape report
- CK-3773274 - Tablets updates RSS · CI watch RSS
- Cytokinetics portfolio CI